LONDON--(BUSINESS WIRE)-- DexCom, Inc. (Nasdaq: DXCM), a global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, today announced both the launch of Dexcom ONE+, a CGM ...

Dexcom is hoping to win FDA approval to begin selling its G7 continuous glucose monitor in the U.S. later this year. (Shown here with an Apple Watch). · MedTech Dive · Courtesy of Dexcom The above ...

The US Food and Drug Administration has cleared the Dexcom G7 15-Day Continuous Glucose Monitor (CGM) for people older than 18 with diabetes. It’s the longest-lasting wearable on the market. The G7 15 ...

This week, Tandem Diabetes Care’s t:slim X2 insulin pump and Control-IQ algorithm made headlines as they became the first to integrate with Dexcom’s G7 sensor to create an artificial pancreas system.

Editor’s note: This post was updated on June 9 to include a statment from Pharmsource. People with diabetes who use the Dexcom G7 continuous glucose monitoring system need to check the lot numbers on ...

Add Yahoo as a preferred source to see more of our stories on Google. The Dexcom G7 Continuous Glucose Monitoring (CGM) System, shown here with an iPhone and an Apple Watch. Dexcom warned patients ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Dexcom has obtained European approval for the latest generation of its wearable diabetes sensor, the G7 continuous glucose monitor, for adults and children ages two and up. Designed to be 60% smaller ...

Add Yahoo as a preferred source to see more of our stories on Google. June 11 (Reuters) - Drug wholesaler Pharmsource LLC said it was unaware the Dexcom glucose ‌sensors it bought from licensed ...